Summit Therapeutics Inc (SMMT) concluded trading on Wednesday at a closing price of $33.23, with 11.77 million shares of worth about $391.03 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 56.67% during that period and on April 23, 2025 the price saw a gain of about 21.50%. Currently the company’s common shares owned by public are about 737.63M shares, out of which, 111.14M shares are available for trading.
Stock saw a price change of 34.97% in past 5 days and over the past one month there was a price change of 60.61%. Year-to-date (YTD), SMMT shares are showing a performance of 86.21% which increased to 849.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.10 but also hit the highest price of $33.89 during that period. The average intraday trading volume for Summit Therapeutics Inc shares is 2.93 million. The stock is currently trading 52.63% above its 20-day simple moving average (SMA20), while that difference is up 61.21% for SMA50 and it goes to 81.35% higher than SMA200.
Summit Therapeutics Inc (NASDAQ: SMMT) currently have 737.63M outstanding shares and institutions hold larger chunk of about 12.61% of that.
The stock has a current market capitalization of $24.51B and its 3Y-monthly beta is at -1.06. It has posted earnings per share of -$0.31 in the same period. It has Quick Ratio of 10.15 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SMMT, volatility over the week remained 10.31% while standing at 11.05% over the month.
Stock’s fiscal year EPS is expected to drop by -37.58% while it is estimated to decrease by -40.72% in next year. EPS is likely to shrink at an annualized rate of -28.25% for next 5-years, compared to annual growth of -10.52% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on March 26, 2025 offering a Buy rating for the stock and assigned a target price range of between $23 and $35 to it. On March 12, 2025, Evercore ISI Initiated their recommendations, while on February 28, 2025, Goldman Initiated their ratings for the stock with a price target of $42. Stock get a Buy rating from Truist on January 08, 2025.
